Key facts
- This page summarizes Mark E. Saad's Form 4 filing for Axsome Therapeutics, Inc. (AXSM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 25 Feb 2025, 19:59.
Mark E. Saad - 21 Feb 2025 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)
- Reporting relationship
- Director
- Issuer ticker
- AXSM
- Reported as of
- 21 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Feb 2025, 19:59:08 UTC
- Prior SEC filing
- 11 Sep 2024
- Next SEC filing
- 10 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nick Pizzie, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark E. Saad filed Form 4 for Axsome Therapeutics, Inc. (AXSM) on 25 Feb 2025.
Change
- Previous filing in this sequence was filed on 11 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXSM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +1,494
- Change %
- Price
- $0.000000
- Shares after
- 1,494
- Date
- 21 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,494
- Exercise price
- $137.75
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents 1,494 options elected to be received in lieu of cash compensation earned in 2024. All of such options are immediately exercisable.